… pigmentosa ProQR is accelerating the development of its Axiomer ® RNA base-editing technology platform across … pigmentosa. ProQR is accelerating the development of its Axiomer RNA editing platform and pipeline activities and … The Company will present further non-clinical data for Axiomer and announce its internal development targets in H2 …
… Results ProQR is accelerating the development of its Axiomer ® RNA base-editing technology platform across … pigmentosa. ProQR is accelerating the development of its Axiomer RNA editing platform and pipeline activities, … The Company will present further non-clinical data for Axiomer and announce its internal development targets in H2 …
… in 2019. QR-313 was granted ODD in the U.S. and Europe. Axiomer ® RNA-editing technology was introduced at the … N.V. entered into a research collaboration to apply Axiomer ® to fibrosis targets selected by Galapagos. Positive … trials and validating our novel RNA-editing technology, Axiomer ® ,” said Daniel A. de Boer, CEO of ProQR. “We are …
… 2022 Operating and Financial Results Development of Axiomer ® RNA base editing technology platform continues … ended September 30, 2022, and provided a business update. Axiomer ® Program and Business Operations Updates Axiomer Program In August, ProQR announced the Company will …
… Board (SAB). In vivo proof of concept data for novel Axiomer ® RNA editing platform technology presented at the … 1/2 trial of QR-110, announcing the in vivo PoC for our Axiomer technology and the completion of the pre-clinical … programs and our novel RNA-editing technology, Axiomer ® . We are also thrilled with the spin out of Amylon …
… transformative RNA therapies based on its proprietary Axiomer® RNA editing technology platform, today announced … 30 days following the presentation date. About Axiomer ® ProQR is pioneering a next-generation RNA base …